7596-74-9

Usage

Uses

Used in Pharmaceutical Industry:
3-(1H-Benzimidazol-2-yl)aniline is used as a building block for the synthesis of biologically active molecules and pharmaceutical compounds due to its unique chemical structure and potential reactivity in chemical processes. Its presence in these compounds can contribute to their therapeutic effects and medicinal properties.
Used in Research Applications:
In the field of research, 3-(1H-Benzimidazol-2-yl)aniline serves as a valuable compound for studying the properties and reactions of aniline and benzimidazole derivatives. Its unique structure allows researchers to explore new avenues in chemical synthesis and investigate its interactions with other molecules.
Used in Organic Chemistry for Material Development:
3-(1H-Benzimidazol-2-yl)aniline may also be utilized in the development of new materials in organic chemistry. Its fusion of a benzimidazole ring with an aniline moiety could lead to the creation of novel materials with specific properties and applications in various industries.

InChI:InChI=1/C13H11N3/c14-10-5-3-4-9(8-10)13-15-11-6-1-2-7-12(11)16-13/h1-8H,14H2,(H,15,16)

Upstream product

• 15456-62-9 2-(3-nitrophenyl)-1H-benzimidazole 
• 99847-32-2 3-nitro-benzoic acid-(2-nitro-anilide) 
• 99-05-8 meta-aminobenzoic acid 
• 95-54-5 1,2-diamino-benzene 
• 70086-34-9 2',3-diaminobenzanilide 
• 7647-01-0 hydrogenchloride 
• 88-74-4 2-nitro-aniline 
• 121-90-4 m-nitrobenzoic acid chloride 
• 39145-59-0 o-phenylenediamine hydrochloride 
• 99-61-6 3-nitro-benzaldehyde 
• 65953-23-3 3-nitro-N-[2-[(3-nitrobenzoyl)amino]phenyl]benzamide 
• 1709-44-0 m-aminobenzaldehyde 
• 121-92-6 3-nitrobenzoic acid 
• 5969-92-6 N-o-aminophenyl m-nitrobenzamide 

Downstream Products

• 76618-02-5 2-Phenyl-3--6-bromo-quinazolin(3H)-4-one 
• 1031126-38-1 N-[3-(1H-benzimidazol-2-yl)phenyl]furan-3-carboxamide 
• 496913-64-5 N-[3-(1H-benzoimidazol-2-yl)-phenyl]-2-(2-thienyl)acetamide 
• 333395-09-8 N-[3-(1H-benzimidazol-2-yl)phenyl]-2,2-dimethylpropanamide 
• 314029-69-1 N-[3-(1H-benzimidazol-2-yl)phenyl]-3-chlorobenzamide 
• 420102-99-4 N-[3-(1H-1,3-benzodiazol-2-yl)phenyl]-3-methoxybenzamide 
• 477486-40-1 N-[3-(1H-benzimidazol-2-yl)phenyl]-3-trifluoromethylbenzamide 

Relevant academic research and scientific papers

Design and synthesis of 2-phenyl benzimidazole derivatives as VEGFR-2 inhibitors with anti-breast cancer activity

Three new series of 2-phenyl benzimidazole-based derivatives were designed, synthesized, and evaluated for their in vitro cytotoxic activity against breast cancer (MCF-7) cell lines. Three compounds 8, 9, and 15 showed high cytotoxic activities, with ICs

In vitro evaluation of the potential pharmacological activity and molecular targets of new benzimidazole-based schiff base metal complexes

Metal-based drugs, including lanthanide complexes, have been extremely effective in clinical treatments against various diseases and have raised major interest in recent decades. Hence, in this work, a series of lanthanum (III) and cerium (III) complexes, including Schiff base ligands derived from (1H-benzimidazol-2-yl)aniline, salicylaldehyde, and 2,4-dihydroxybenzaldehyde were synthesized and characterized using different spectroscopic methods. Besides their cytotoxic activities, they were examined in human U-937 cells, primate kidney non-cancerous COS-7, and six other, different human tumor cell lines: U251, PC-3, K562, HCT-15, MCF-7, and SK-LU-1. In addition, the synthesized compounds were screened for in vitro antiparasitic activity against Leishmania braziliensis, Plasmodium falciparum, and Trypanosoma cruzi. Additionally, antibacterial activities were examined against two Gram-positive strains (S. aureus ATCC 25923, L. monocytogenes ATCC 19115) and two Gram-negative strains (E. coli ATCC 25922, P. aeruginosa ATCC 27583) using the microdilution method. The lanthanide complexes generally exhibited increased biological activity compared with the free Schiff base ligands. Interactions between the tested compounds and model membranes were examined using differential scanning calorimetry (DSC), and interactions with calf thymus DNA (CT-DNA) were investigated by ultraviolet (UV) absorption. Molecular docking studies were performed using leishmanin (1LML), cruzain (4PI3), P. falciparum alpha-tubulin (GenBank sequence CAA34101 [453 aa]), and S. aureus penicillin-binding protein 2a (PBP2A; 5M18) as the protein receptors. The results lead to the conclusion that the synthesized compounds exhibited a notable effect on model membranes imitating mammalian and bacterial membranes and rolled along DNA strands through groove interactions. Interactions between the compounds and studied receptors depended primarily on ligand structures in the molecular docking study.

Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights

Introduction: Epidermal growth factor receptor (EGFR) inhibition is an imperative therapeutic approach targeting various types of cancer including colorectal, lung, breast, and pancreatic cancer types. Moreover, cyclooxygenase-2 (COX-2) is frequently over

Efficient and facile synthesis of benzimidazole induced schiff bases and their potent antibacterial activity and computational study

Synthesized benzimidazole induced Schiff base analogues were characterized by mass, 13C NMR, 1H NMR and UV-visible spectroscopy. To get more information about binding mechanism, molecular docking studies were carried out and the obtained results concluded

2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES

A genus of compounds encompassed by formula (III) and their use is disclosed: Formula (III). The compounds activate Ppargc1a and, as a consequence, are useful for treating a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, motor neuron diseases, and a demyelinating disease.

Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120

Attachment of envelope glycoprotein gp120 to the host cell receptor CD4 is the first step during the human immunodeficiency virus-1 (HIV-1) entry into the host cells that makes it a promising target for drug design. To elucidate the crucial three dimensional (3D) structural features of reported HIV-1 gp120 CD4 binding inhibitors, 3D pharmacophores were generated and receptor based approach was employed to quantify these structural features. A four-partial least square factor model with good statistics and predictive ability was generated for the dataset of 100 molecules. To further ascertain the structural requirement for gp120-CD4 binding inhibition, molecular interaction studies of inhibitors with gp120 was carried out by performing molecular docking using Glide 5.6. Based on these studies, structural requirements were drawn and new molecules were designed accordingly to yield new sulphonamides derivatives. A water based green synthetic approach was adopted to obtain these compounds which were evaluated for their HIV-1 gp120 CD4 binding inhibition. The newly synthesized compounds exhibited remarkable activity (10-fold increase) when compared with the standard BMS 806. Further the stability of newly synthesized derivatives with HIV-1 gp120 was also investigated through molecular dynamics simulation studies. This provides a proof of concept for molecular modeling based design of new inhibitors for inhibition of HIV-1 gp120 CD4 interaction.

Benzimidazole derivative and application thereof

The invention relates to the field of medicinal chemistry, in particular to a 3-(1H-benzo [d] imidazole-2-yl) aniline derivative with alpha-glucosidase inhibition activity, and the structural generalformula of the derivative is shown in the specification.

Benzimidazole ring-containing propyne amide derivative as well as preparation method and pharmaceutical composition and application thereof

The invention relates to a benzimidazole ring-containing propiolamide derivative as shown in the formula I, its medicinal salt and their preparation method, a composition containing one or more of the compounds and an application of the compounds in treating tumor diseases.

Reevaluating the synthesis of 2,5-disubstituted-1H-benzimidazole derivatives by different green activation techniques and their biological activity as antifungal and antimicrobial inhibitor

A comparative study concerned with the preparation of diversely substituted-1H-benzimidazole under different green activation techniques and conventional methods is reported. Data are collected for infrared, ultrasound, microwave, and simultaneous irradiation with US and IR sources, as this last strategy shows an important improvement. Further, the small library of potentially bioactive benzimidazole 17-76 synthesized was screened as an antifungal and antimicrobial agent. Strong activity against Candida albicans and Staphylococcus aureus was observed. Remarkably, 2-(4-aminophenyl)-5-phenylamino-1H-benzimidazole 63 resulted better than that of reference drugs miconazole with a zone of inhibition up to 42 mm. Likewise, 2-(2-aminophenyl)-1H-benzimidazole 21 showed substantial antimicrobial activity against MRSA strain. When assayed by the microdilution method, this azaheterocyclic compound presented a minimum inhibitory concentration (MIC) ≥ 16.4 μg/100 mL and a bacterial percentage reduction of 96%.

New pyrimidine-benzoxazole/benzimidazole hybrids: Synthesis, antioxidant, cytotoxic activity, in vitro cyclooxygenase and phospholipase A2-V inhibition

To enhance the cytotoxicity of benzimidazole and/or benzoxazole core, the benzimidazole/benzoxazole azo-pyrimidine were synthesized through diazo-coupling of 3-aminophenybenzimidazole (6a) or 3-aminophenylbenzoxazole (6b) with diethyl malonate. The new az